Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac N.V. stock logo
CVAC
CureVac
$4.66
$4.66
$3.13
▼
$5.72
$1.05B1.77992,546 shsN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$15.33
+1.8%
$15.00
$11.02
▼
$28.00
$1.06B1.81777,989 shs814,432 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.05
+0.2%
$11.64
$9.46
▼
$23.29
$940.47M1.141.53 million shs1.32 million shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$2.83
-2.9%
$3.08
$2.44
▼
$5.15
$254.50M0.67651,139 shs764,581 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac N.V. stock logo
CVAC
CureVac
0.00%0.00%0.00%0.00%-10.73%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-2.78%-5.10%+1.35%-29.43%+20.87%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+2.22%-14.30%+6.88%-30.01%-18.54%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-9.06%-5.52%+1.04%-23.02%-24.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CureVac N.V. stock logo
CVAC
CureVac
$4.66
$4.66
$3.13
▼
$5.72
$1.05B1.77992,546 shsN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
$15.33
+1.8%
$15.00
$11.02
▼
$28.00
$1.06B1.81777,989 shs814,432 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.05
+0.2%
$11.64
$9.46
▼
$23.29
$940.47M1.141.53 million shs1.32 million shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$2.83
-2.9%
$3.08
$2.44
▼
$5.15
$254.50M0.67651,139 shs764,581 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CureVac N.V. stock logo
CVAC
CureVac
0.00%0.00%0.00%0.00%-10.73%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-2.78%-5.10%+1.35%-29.43%+20.87%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+2.22%-14.30%+6.88%-30.01%-18.54%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-9.06%-5.52%+1.04%-23.02%-24.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CureVac N.V. stock logo
CVAC
CureVac
1.00
SellN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
2.90
Moderate Buy$51.00232.79% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.60
Moderate Buy$31.33183.56% Upside
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
2.73
Moderate Buy$12.00324.78% Upside

Current Analyst Ratings Breakdown

Latest SABS, JBIO, CVAC, and MLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Reiterated RatingBuy
11/16/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Lower Price TargetBuy$47.00 ➝ $41.00
11/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/12/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Set Price TargetOutperform$34.00
11/6/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Initiated CoverageBuy$57.00
10/27/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Reiterated RatingBuy$77.00
10/5/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Reiterated RatingBuy$50.00
10/1/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Reiterated RatingOutperform$47.00
10/1/2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
Reiterated RatingBuy$55.00
9/17/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
UpgradeSell (E+) ➝ Sell (D-)
9/16/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Reiterated RatingOverweight
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CureVac N.V. stock logo
CVAC
CureVac
$70.74M14.78$0.99 per share4.73$3.36 per share1.39
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/A$6.58 per shareN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.48 per shareN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$1.32M192.81$0.30 per share9.37$2.34 per share1.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$127.41M-$1.86N/AN/AN/AN/A-42.80%-40.09%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.67N/AN/AN/AN/A-79.95%-56.40%N/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$13.27M-$1.33N/AN/AN/AN/A-40.04%-35.98%N/A

Latest SABS, JBIO, CVAC, and MLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
-$0.73-$0.42+$0.31-$0.42N/AN/A
11/5/2026Q3 2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$0.2746-$0.24+$0.0346-$0.24$0.13 millionN/A
11/4/2026Q3 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.8326-$0.93-$0.0974-$0.93N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CureVac N.V. stock logo
CVAC
CureVac
0.03
3.70
3.69
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
16.03
14.93
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.26
9.13
9.13
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.01
7.28
7.28

Institutional Ownership

CompanyInstitutional Ownership
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.82%

Insider Ownership

CompanyInsider Ownership
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
23.06%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionNo Data
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
5569.19 million53.23 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
8690.09 million83.43 millionOptionable

Recent News About These Companies

FY2026 EPS Estimate for SAB Biotherapeutics Cut by Analyst
SAB Biotherapeutics (SABS) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

CureVac stock logo

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)
As of 11/19/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Jade Biosciences stock logo

Jade Biosciences NASDAQ:JBIO

$15.32 +0.27 (+1.76%)
Closing price 03:58 PM Eastern
Extended Trading
$15.32 -0.01 (-0.07%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.05 +0.02 (+0.18%)
Closing price 03:58 PM Eastern
Extended Trading
$11.08 +0.02 (+0.23%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABS

$2.82 -0.09 (-2.92%)
Closing price 03:58 PM Eastern
Extended Trading
$2.81 -0.02 (-0.53%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.